AMED SCARDA「ワクチン開発のための世界トップレベル研究開発拠点の形成事業」合同シンポジウム

Masaki Ishibashi¹, *日永田 純一¹, Hidetoshi Hamamoto¹ (1. MedRx Co., Ltd. (Japan))

Takayuki Nakamura¹, *Yuki Katagiri¹, Yasuyuki Shiraishi¹, Takashi Kamishita², Toshiaki Takagi², Natsumi Kodake², Takashi Miyazaki² (1. TaiseiKako Co,.Ltd (Japan), 2. TOKO YAKUHINKOGYO CO.,LTD. (Japan))

*Tetsuo Yoshida^1,2, Rena Akahori^2,3, Akiko Yanagiya², Naoki Matsumoto², Daichi Matsuura², Hayato Sato², Hiroaki Murakami², Tomohiro Sawadaishi², Yanwen Feng², Jun Nihira², Satoshi Abe², Kazuyuki Nakashima² (1. Axcelead, Inc. (Japan), 2. ARCALIS, Inc. (Japan), 3. Hitachi, Ltd. (Japan))

*Takuya Hasegawa¹, Hideyuki Kawamoto¹, Taro Iwasa¹ (1. Sysmex Corp. (Japan))

*都築 拓¹, Tsuyoshi Tatsukawa¹, Yosuke Ozawa² (1. Epistra Inc. / cSIMVa Chiba University (Japan), 2. Epistra Inc. (Japan))

*Satoru Kobayashi¹, Noriaki Matsuda¹ (1. 3-D Matrix, Ltd (Japan))

*Hideki Ishiwata¹, Takashi Mochizuki¹ (1. Daiichi Sankyo Co., Ltd. Vaccine Business Department (Japan))

*Akihito Sawada¹, Yusuke Okada¹, Takeru Yamakawa¹ (1. Infectious Disease Control Labs, Group 1 Drug Discovery Department Meiji Seika Pharma Co., Ltd. (Japan))

*Po-hung Wang¹, Shuhei Taguwa², Kazuo Yamashita¹ (1. KOTAI Biotechnologies, Inc. (Japan), 2. Osaka University (Japan))

*Ryota Ise¹, Yo Sonoda¹ (1. SNBL, Ltd. (Japan))

*Yuichi Yoshimura¹ (1. Nipro Corporation (Japan))

*Masafumi Endo¹, Yasuhiko Shinmura¹ (1. KM Biologics Co., Ltd. (Japan))

*Yoko Yoshimura¹, Kentaro Kasama¹, Masayoshi Imada¹, Yoshinao Kobayashi¹ (1. Nobelpharma Co., Ltd. (Japan))

*Kazuhide Onoguchi¹ (1. NEC Corporation (Japan))

masahiro oda¹, *PeiQing Zhang¹ (1. Global Life Science Technologies Japan (Cytiva) (Japan))